[go: up one dir, main page]

WO1995031981A3 - Methods and compositions for reducing multidrug resistance - Google Patents

Methods and compositions for reducing multidrug resistance Download PDF

Info

Publication number
WO1995031981A3
WO1995031981A3 PCT/US1995/006167 US9506167W WO9531981A3 WO 1995031981 A3 WO1995031981 A3 WO 1995031981A3 US 9506167 W US9506167 W US 9506167W WO 9531981 A3 WO9531981 A3 WO 9531981A3
Authority
WO
WIPO (PCT)
Prior art keywords
multidrug resistance
compositions
present
methods
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/006167
Other languages
French (fr)
Other versions
WO1995031981A2 (en
Inventor
John S Coon
Mannarsamy Balasubramanian
R Martin Emanuele
Himashu Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush Presbyterian St Lukes Medical Center
Original Assignee
Rush Presbyterian St Lukes Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush Presbyterian St Lukes Medical Center filed Critical Rush Presbyterian St Lukes Medical Center
Priority to AU26894/95A priority Critical patent/AU2689495A/en
Priority to EP95922084A priority patent/EP0759753A1/en
Publication of WO1995031981A2 publication Critical patent/WO1995031981A2/en
Publication of WO1995031981A3 publication Critical patent/WO1995031981A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.
PCT/US1995/006167 1994-05-19 1995-05-19 Methods and compositions for reducing multidrug resistance Ceased WO1995031981A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU26894/95A AU2689495A (en) 1994-05-19 1995-05-19 Methods and compositions for reducing multidrug resistance
EP95922084A EP0759753A1 (en) 1994-05-19 1995-05-19 Methods and compositions for reducing multidrug resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24603794A 1994-05-19 1994-05-19
US08/246,037 1994-05-19

Publications (2)

Publication Number Publication Date
WO1995031981A2 WO1995031981A2 (en) 1995-11-30
WO1995031981A3 true WO1995031981A3 (en) 1996-07-18

Family

ID=22929080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/006167 Ceased WO1995031981A2 (en) 1994-05-19 1995-05-19 Methods and compositions for reducing multidrug resistance

Country Status (4)

Country Link
EP (1) EP0759753A1 (en)
AU (1) AU2689495A (en)
CA (1) CA2190636A1 (en)
WO (1) WO1995031981A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011668A1 (en) * 1991-12-10 1993-06-24 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011668A1 (en) * 1991-12-10 1993-06-24 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.S.-F- CHONG ET AL.: "Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells", CANCER IMMUNOL. IMMUNOTHER., vol. 36, no. 2, 1993, pages 133 - 139, XP002000100 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, M. PAGE ET AL.: "Elimination of P-170 mediated multidrug resistance by solubilization in pluronic micelles", XP002000101 *
J.S. COON ET AL.: "Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid reverses multidrug resistance", CANCER RESEARCH, vol. 51, February 1991 (1991-02-01), pages 897 - 902, XP002000098 *
J.S. COON: "Survey of surfactants for reversing multidrug resistance", PROC. AM. ASSOC. CANCER. RES. ANN. MEET., vol. 33, no. 0, 1992, pages 484, XP002000099 *
L.E. BUCKINGHAM ET AL.: "Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents", INT. J. CANCER, vol. 62, no. 4, August 1995 (1995-08-01), pages 436 - 442, XP002000097 *
PROC. AM. ASSOC. CANCER RES. ANNU MEET, vol. 33, no. 0, 1992, pages 552 *
R. PARADIS ET AL.: "Use of pluronic micelles to overcome multidrug resistance", INT. J. ONCOL., vol. 5, no. 6, 1994, pages 1305 - 1308, XP002000096 *

Also Published As

Publication number Publication date
AU2689495A (en) 1995-12-18
CA2190636A1 (en) 1995-11-30
EP0759753A1 (en) 1997-03-05
WO1995031981A2 (en) 1995-11-30

Similar Documents

Publication Publication Date Title
AU1937395A (en) Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
NZ506058A (en) Antibacterial 9-substituted tetracyclines, and pharmaceuticals and uses thereof
CA2186673A1 (en) The use of fatty acids in the treatment of huntington's chorea
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
AU7943491A (en) Essential fatty acid compositions
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
WO1997039759A3 (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
AUPP437698A0 (en) Methods for treatment of coronary, carotid and other vascular disease
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
CA2183549A1 (en) Acidified nitrite as an antimicrobial agent
PT774962E (en) USING DHA AS A PHARMACEUTICAL COMPOSITION
ZA937148B (en) Dioic acids.
BR0008912A (en) Strains of lactic acid bacteria capable of preventing diarrhea
IL134056A0 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
AU2002211536A1 (en) Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals
CA2254682A1 (en) Method of treating eye infections with azithromycin
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
ATE221783T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILLUS PLANTARUM AND ARGININE
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
EP0795604A3 (en) Strains of bacteria with altered metabolism of bile acids and their use
WO2003009859A1 (en) Immunotherapy for humans
HK1044896A1 (en) Method of treating hiv infection and related secondary infections thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2190636

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995922084

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995922084

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995922084

Country of ref document: EP